Brief: CanSino Biologics Gets Clinical Trial Approval From NMPA To Initiate Clinical Trial For PCV24
05/01/2026 10:27
Jan 5 (Reuters) - CanSino Biologics Inc 688185.SS: GOT CLINICAL TRIAL APPROVAL FROM NMPA OF CHINA TO INITIATE RELEVANT CLINICAL TRIAL FOR PCV24 Further company coverage: 688185.SS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cansino Biologics
See all newsBrief: CanSino Biologics Says China's NMPA Granted Priority Review Status To NDA For TD5CP Adolescent, Adult
Brief: CanSino Biologics Reports Widened Net Loss For Q1
Brief: CanSino Biologics Says 2025 Net Profit At 27.9 Million Yuan
Brief: CanSino Biologics Prelim 2025 Net Profit At 27.9 Million Yuan
Brief: CanSino Biologics Expects To Have Returned to Net Profit In 2025